Skip to main content
Department of Pathology Department of Pathology
  1. Department of Pathology
  2. Research
  3. Faculty Labs
  4. Cheresh Lab
  5. Publications

Cheresh Lab Publications:

Most Highly Cited Papers

h-index = 138, see Google Scholar:

Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 1994;264:569-71. PubMed link Cited by 3916

Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994;79:1157-64. PubMed link Cited by 3125

Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell, 1993 Apr 23;73(2):309-19. PubMed link Cited by 2816

Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell, 1996 May 31;85(5):683-93. PubMed link Cited by 2092

Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science, 1995 Dec 1;270(5241):1500-2. PubMed link Cited by 1815

Ongoing Research

Papers Relevant to Ongoing Research:

Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prévost N, Tarin D, Shattil SJ and Cheresh DA. Integrin αvβ3/c-src “Oncogenic Unit” Promotes Anchorage-independence and Tumor Progression. Nature Medicine, 2009; 15:1163-1169, PMCID: 2759406. PubMed link

Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM and Cheresh DA. A β3 integrin-KRAS-RalB complex drives tumor stemness and resistance to EGFR inhibition. Nature Cell Biology, 2014; 16: 457-468, PMCID: 4105198. PubMed link

Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott K, Cosset E, Lesperance J, Weis SM, and Cheresh DA. Galectin-3, a druggable vulnerability for KRAS-addicted cancers. Cancer Discovery, 2017. September 11 2017 DOI:10.1158/2159-8290.CD-17-0539. PubMed link

Cosset E, Ilmjarv S, Dutoit V, Elliott KC, von Schalscha TL, Camargo MF, Reiss A, Moroshi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, Dieterich P, Weis SM, Mischel PS and Cheresh DA. Glut3 addiction is a druggable vulnerability for a molecularly defined subpopulation of glioblastoma. Cancer Cell, 2017; 32(6):856-868. PubMed link

Wettersten HI, Weis SM, Pathria P, von Schalscha T, Minami T, Varner JA, and Cheresh DA. Arming tumor-associated macrophages to reverse epithelial cancer progression. Cancer Research, 2019; 79(19):5048-5059. PubMed link

Wu C, Rakhshandehroo T, Wettersten HI, Campos A, von Schalscha T, Jain S, Yu Z, Tan J, Mose E, Childers BG, Lowy AM, Weis SM, Cheresh DA. Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation. Nat Cell Biol. 2023 Feb;25(2):309-322. PubMed link

Cheresh Lab publications